The purpose of this study is to evaluate overall survival and immunological monitoring for peptide vaccination therapy using novel cancer testis antigens (STF-II) for locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma
The phase II multicenter trial of vaccination study using peptides derived from URLC10, CDCA1, and KOC1 for locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) who had failed for the standard therapy are performed to evaluate the survival benefit of the cancer vaccination.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
60
Biological/Vaccine: URLC10, CDCA1, and KOC1 peptides
University of Yamanashi, First Department of Surgery
Chūō, Yamanashi, Japan
RECRUITINGoverall survival
Time frame: death from start of treatment
CTL response
Time frame: CTL response after 5 round vaccination
DTH response
Time frame: Skin reaction after 5 round vaccination
Progression free survival
Time frame: time from start of vaccination until disease progreesion
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.